본문 바로가기

바이오스펙테이터

기사본문

ImmunOncia, 'CD47 Player' reasons as Best-In-Class

입력 2020-10-28 13:12 수정 2020-11-12 19:46

by Sungmin Kim

이 기사는 '프리미엄 뉴스서비스 BioS+' 기사입니다.
What is the differentiability of the ‘2nd Generation CD47 Asset’ of ImmuneOncia in the perspective of global competition landscape

In the field of immuno-oncology therapeutics, CD47 is emerging as a next-generation therapeutic target of immunity gateway succeeding PD-(L)1. Different from PD-(L)1 activating T-Cells, CD47 activates macrophages, thus manifesting the potential of drugs for regulating innate immunity. Clinically, CD47 exhibits broad expandability with sole antitumor activity activity having excellent efficacy after co-administration with antibody anticancer agents or chemotherapy. In this respect, the path of ImmuneOncia, a domestic leading company of immuno-oncology agent, is significant.

Currently, two immuno-oncology agents of ImmuneOncia are at the stage of clinical development. The domestic Phase II Clinical Trial for PD-L1 antibody ‘IMC-001’ and the Phase I Clinical Trial for CD47 antibody ‘IMC-002’ in the United States are in progress. Among them, ‘CD47 Asset’ is expected to become as one of the ‘Best-in-Class’.

CEO SONG Yun Jeong of ImmuneOncia stated and introduced current situation of market as follows: “… the success of CD47 is prefigured by the leading medicine, ‘magrolimab (Hu5F9-G4)’, which is in at the stage of approval for clinical trial. However, the issue of manifestation of RBC combining with CD47 by the drug needs to be resolved …”, “… IMC-002 is the 2nd generation CD47 for which its drug-specificity and safety have been improved for unmet needs for drugs with improved drug-fastness and convenience for administration in clinics …”.

In global academic conferences, ImmuneOncia intends to present its preclinical trial data of IMC-002 at the SITC in USA this November. The company is also accelerating the development of subsequent projects. ImmuneOncia currently promotes the excavation of (confidential) project targeting new T-Cell immuno-gateway molecules. In addition, the company is developing a franchise of bispecific antibody (BsAb) based on CD47 or PD-L1 including a duplicated CD47/PD-L1 antibody to increase tumor-specificity....

'프리미엄 뉴스서비스 BioS+'는 독자들에게 가치(value)있는 기사를 제공합니다.
추가내용은 유료회원만 이용할 수 있습니다.
회원이시면 로그인 해주시고, 회원가입을 원하시면 클릭 해주세요.
카카오스토리로 기사 공유하기